Summary:
The primary objective to the study is to assess whether treatment with pemafibrate will prevent cardiovascular events in adults with type 2 diabetes who have elevated triglycerides and HDL-C and are at high risk for future cardiovascular events.
Qualified Participants Must:
• Be currently taking a statin for cholesterol control (if not currently taking a statin, must be intolerant to at least 2 statins)
•
Be Diagnosed with type 2 diabetes or have an A1C greater than 6.5 or Glucose greater than 129
•
Not currently be taking any fibrate medications
Qualified Participants May Receive:
- Compensation for time and travel expenses
- Lab work and study provided medication
- Physicals performed by a board certified physician